Search Results

A Comparison of Costs among Patients with Type 2 Diabetes Mellitus Who Initiated Therapy with Exenatide or Insulin Glargine

Authors: Misurski, Derek; Lage, Maureen J.; Fabunmi, Rosalind; Boye, Kristina S.

Source: Applied Health Economics and Health Policy, Volume 7, Number 4, 1 December 2009 , pp. 245-254(10)

Publisher: Adis International

Evidence linking Lantus to higher cancer risk inconclusive − Medsafe

Source: Reactions, Volume 1, Number 1272, 2009-10-03 , pp. 3-3(1)

Publisher: Adis International

Health Canada is reviewing the potential association between insulin glargine [Lantus] and an increased risk of cancer

Source: Reactions, Volume 1, Number 1261, 2009-07-18 , pp. 3-3(1)

Publisher: Adis International

Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects

Authors: Becker; Frick; Teichert; Nosek; Heinemann; Heise; Rave

Source: Diabetes, Obesity and Metabolism, Volume 10, Number 11, November 2008 , pp. 1105-1113(9)

Publisher: Blackwell Publishing

Insulin glargine and its role in glycaemic management of Type 2 diabetes

Authors: Elrishi, MA; Jarvis, J; Khunti, K; Davies, MJ

Source: Expert Opinion on Drug Metabolism and Toxicology, Volume 4, Number 8, August 2008 , pp. 1099-1110(12)

Publisher: Informa Healthcare

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial

Authors: Davies; Lavalle-González; Storms; Gomis

Source: Diabetes, Obesity and Metabolism, Volume 10, Number 5, May 2008 , pp. 387-399(13)

Publisher: Blackwell Publishing

Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice

Authors: Schreiber, Stephan A.; Russmann, Anika

Source: Current Medical Research and Opinion, Volume 23, Number 12, December 2007 , pp. 3131-3136(6)

Publisher: Informa Healthcare

Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK

Authors: Davies; Evans; Storms; Gomis; Khunti

Source: Diabetes, Obesity and Metabolism, Volume 9, Number 5, September 2007 , pp. 706-713(8)

Publisher: Blackwell Publishing

Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients

Authors: Schreiber; Haak

Source: Diabetes, Obesity and Metabolism, Volume 9, Number 1, January 2007 , pp. 31-38(8)

Publisher: Blackwell Publishing

The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice

Authors: Schreiber, Stephan A.; Russmann, Anika

Source: Current Medical Research and Opinion, Volume 22, Number 2, February 2006 , pp. 335-341(7)

Publisher: Informa Healthcare

Use of insulin glargine in children under age 6 with type 1 diabetes

Authors: Dixon, Brenner; Peter Chase, H; Burdick, Jonathan; Fiallo-Scharer, Rosanna; Walravens, Philippe; Klingensmith, Georgeanna; Rewers, Marian; Garg, Satish K

Source: Pediatric Diabetes, Volume 6, Number 3, September 2005 , pp. 150-154(5)

Publisher: Blackwell Publishing

Initiation of insulin glargine in children and adolescents with type 1 diabetes

Authors: Tan C.Y.; M. Wilson D.; Buckingham B.

Source: Pediatric Diabetes, Volume 5, Number 2, June 2004 , pp. 80-86(7)

Publisher: Blackwell Publishing

Aventis has launched insulin glargine [`Lantus'] in France.

Source: Inpharma, Volume 1, Number 1403, 2003 , pp. 18-18(1)

Publisher: Adis International

Biotransformation of insulin glargine after subcutaneous injection in healthy subjects

Authors: Kuerzel, G.U.; Shukla, U.; Scholtz, H.E.; Pretorius, S.G.; Wessels, D.H.; Venter, C.; Potgieter, M.A.; Lang, A.M.; Koose, T.; Bernhardt, E.

Source: Current Medical Research and Opinion, Volume 19, Number 1, 1 February 2003 , pp. 34-40(7)

Publisher: Informa Healthcare

No evidence for accumulation of insulin glargine (LANTUS®): a multiple injection study in patients with Type 1 diabetes

Authors: Heise, T.; Bott, S.; Rave, K.; Dressler, A.; Rosskamp, R.; Heinemann, L.

Source: Diabetic Medicine, Volume 19, Number 6, June 2002 , pp. 490-495(6)

Publisher: Blackwell Publishing

Evaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and Mice

Authors: Stammberger I.; Bube A.; Durchfeld-Meyer B.; Donaubauer H.; Troschau G.

Source: International Journal of Toxicology, Volume 21, Number 3, 1 May 2002 , pp. 171-179(9)

Publisher: Informa Healthcare

Evaluation of the Reproductive Toxicity and Embryotoxicity of Insulin Glargine (LANTUS) in Rats and Rabbits

Authors: Hofmann T.; Horstmann G.; Stammberger I.

Source: International Journal of Toxicology, Volume 21, Number 3, 1 May 2002 , pp. 181-189(9)

Publisher: Informa Healthcare

Leaf growth in the fast-growing Holcus lanatus and the slow-growing Deschampsia flexuosa: tissue maturation

Authors: Groeneveld, HW; Bergkotte, M; Lambers, H

Source: Journal of Experimental Botany, Volume 49, Number 326, September 1998 , pp. 1509-1517(9)

Publisher: Oxford University Press